Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors, many of which are beyond the Company's control, including but not limited to risks related to research and development activities, scientific and technical challenges, formulation and manufacturing difficulties, clinical study preparation and execution, bioanalytical testing, pharmacokinetic outcomes, safety and tolerability findings, the possibility that preclinical or early-stage results may not be predictive of future clinical results, uncertainties relating to regulatory review and approval processes, intellectual property protection and enforcement risks, reliance on third-party advisors, contract research organizations, manufacturers, development partners and suppliers, competitive technologies, market acceptance, financing availability, and general economic, financial, regulatory, and capital market conditions
miR-133: Known as the guardians of the heart, miR-133 is instrumental in suppressing cardiac hypertrophy
The interactions between glutathione and medicines are not fully understood
Human trial Research Disclaimer: Doses reported below are from published preclinical research protocols
GLP-1 therapies may also increase the risk of pancreatitis, although this concern seems to have abated in the last 2 years [36,37,38,39]
